LeMaitre Vascular Files 8-K: Director Changes & Officer Comp Updates
Ticker: LMAT · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1158895
| Field | Detail |
|---|---|
| Company | Lemaitre Vascular Inc (LMAT) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, director-changes
Related Tickers: LMAT
TL;DR
LeMaitre Vascular's 8-K: Director out, new director in, exec pay changes. Governance update.
AI Summary
On June 3, 2024, LeMaitre Vascular, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of a new director, and updates to compensatory arrangements for certain officers. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on corporate governance and executive compensation, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and does not indicate any immediate financial distress or significant operational shifts.
Key Players & Entities
- LeMaitre Vascular, Inc. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 63 Second Avenue, Burlington, Massachusetts 01803 (address) — Principal Executive Offices
- 781-221-2266 (phone_number) — Registrant's Telephone Number
FAQ
Who is the departing director and who is the newly elected director?
The filing indicates the departure of a director and the election of a new director, but specific names are not provided in the provided text.
What specific changes were made to the compensatory arrangements of certain officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not detailed in the provided text.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not specified in the provided text.
What is the primary business of LeMaitre Vascular, Inc.?
LeMaitre Vascular, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its SIC code 3841.
When is LeMaitre Vascular, Inc.'s fiscal year end?
LeMaitre Vascular, Inc.'s fiscal year ends on December 31st.
Filing Stats: 1,122 words · 4 min read · ~4 pages · Grade level 10.8 · Accepted 2024-06-03 16:21:10
Filing Documents
- lmat20240603_8k.htm (8-K) — 31KB
- ex_683041.htm (EX-10.1) — 83KB
- 0001437749-24-019032.txt ( ) — 265KB
- lmat-20240603.xsd (EX-101.SCH) — 3KB
- lmat-20240603_def.xml (EX-101.DEF) — 11KB
- lmat-20240603_lab.xml (EX-101.LAB) — 15KB
- lmat-20240603_pre.xml (EX-101.PRE) — 11KB
- lmat20240603_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. (a) On June 3, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 22,445,999 shares of the Company's common stock were entitled to vote as of April 5, 2024, the record date for the Annual Meeting, of which 20,754,390.159778 shares were present in person or represented by proxy at the Annual Meeting. (b) Matters voted upon by the stockholders at the Annual Meeting were: (i) the election of three Class III directors nominated by the Board of Directors for three-year terms; (ii) an advisory vote on the compensation of the Company's named executive officers; (iii) approval of the Fourth Amended and Restated 2006 Stock Option and Incentive Plan; and (iv) the ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2024. Set forth below is information concerning each matter submitted to a vote at the Annual Meeting. Proposal No.1 – Election of Directors By a majority of votes cast, the stockholders elected the following three nominees as Class III directors for a term of three years expiring upon the 2027 Annual Meeting of Stockholders or until their successor has been duly elected and qualified. John J. O'Connor received a vote of 18,829,637.159778 shares for, 915,672 shares withheld and 1,009,081 broker non-votes. Joseph P. Pellegrino, Jr. received a vote of 16,654,880.159778 shares for, 2,933,313 shares withheld and 1,166,197 broker non-votes. Lawrence J. Jasinski received a vote of 8,277,096.159778 shares for, 11,308,332 shares withheld and 1,168,962 broker non-votes. Having received fewer votes "for" his election than votes "against" his election, on June 3, 2024, Mr. Jasinski tendered his resignation, subject to Board approval, in accordance with the Company's Corporate Governance Guidelines. The Board met on June 3, 2024, and rejected Mr. Jasinski's resignation after considering the re
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 LeMaitre Vascular, Inc. Fourth Amended and Restated 2006 Stock Option and Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEMAITRE VASCULAR, INC. Dated: June 3, 2024 By: /s/ Joseph P. Pellegrino, Jr. Nme: Joseph P. Pellegrino, Jr. Title: Chief Financial Officer and Secretary